Summary
This laboratory study identifies P-REX2a as a prognostic marker in endometrial endometrioid malignancies, demonstrating that elevated P-REX2a expression enhances cancer cell motility through GPCR-mediated signalling pathways independently of PTEN function. The findings suggest P-REX2a expression is associated with poor patient prognosis and may serve as a potential therapeutic target. The research contributes to understanding molecular mechanisms driving endometrial cancer progression.
UK applicability
This mechanistic oncology research may inform biomarker development and therapeutic targeting strategies for endometrial cancer management within UK clinical practice, though further validation in larger patient cohorts would be required before clinical implementation.
Key measures
P-REX2a expression levels; cell motility assays; GPCR downstream pathway activation; PTEN-independent signalling; patient prognosis correlation
Outcomes reported
The study examined the association between P-REX2a protein expression levels and clinical prognosis in endometrial malignancies, specifically endometrioid tumours. The research measured cell motility and signalling pathway activation in relation to P-REX2a expression.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.